Castle Biosciences (CSTL) Rating Maintained as Price Target Lowered | CSTL Stock News

Author's Avatar
May 06, 2025
Article's Main Image

Castle Biosciences (CSTL, Financial) continues to be a focus of attention following a recent update from Lake Street analyst, Thomas Flaten. The analyst has maintained a "Buy" rating on the stock, reflecting sustained confidence in the company's future performance despite a change in its price target.

On May 6, 2025, it was reported that the price target for Castle Biosciences (CSTL, Financial) has been lowered from $40.00 to $35.00 USD. This adjustment marks a 12.50% decrease. The decision to lower the price target indicates a recalibration of expectations but does not reflect a change in the underlying rating, which remains at "Buy."

The revised price target of $35.00 USD suggests ongoing potential for appreciation in Castle Biosciences (CSTL, Financial) stock despite the downward adjustment. Investors and stakeholders of Castle Biosciences should note that the maintained "Buy" rating signals continued support from the analyst, even as market conditions and forecasts evolve.

Wall Street Analysts Forecast

1919899217153912832.png

Based on the one-year price targets offered by 9 analysts, the average target price for Castle Biosciences Inc (CSTL, Financial) is $38.33 with a high estimate of $44.00 and a low estimate of $30.00. The average target implies an upside of 130.65% from the current price of $16.62. More detailed estimate data can be found on the Castle Biosciences Inc (CSTL) Forecast page.

Based on the consensus recommendation from 9 brokerage firms, Castle Biosciences Inc's (CSTL, Financial) average brokerage recommendation is currently 1.4, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for Castle Biosciences Inc (CSTL, Financial) in one year is $29.00, suggesting a upside of 74.49% from the current price of $16.62. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Castle Biosciences Inc (CSTL) Summary page.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.